Your session is about to expire
← Back to Search
TNX-102 SL for Post-COVID Syndrome (PREVAIL Trial)
PREVAIL Trial Summary
This trial will evaluate if TNX-102 SL 5.6 mg can help manage multi-site pain associated with Long COVID. The trial will last 14 weeks and compare TNX-102 SL 5.6 mg to a placebo.
- Post-COVID Syndrome
- Coronavirus
- COVID-19
PREVAIL Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 3 trial • 158 Patients • NCT02015234PREVAIL Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are male or female, 18 to 65 years of age, inclusive.You have a polymerase chain reaction (PCR) confirmed history of SARS-CoV-2 infection at least 3 months prior to enrollment, based on a documented written positive viral test at the time of active infection.You have had pain for at least 3 months, but not more than 18 months, that started or got worse after you had COVID-19.
- Group 1: TNX-102 SL Tablet, 5.6 mg
- Group 2: Placebo SL Tablet
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this clinical trial have an upper age limit for participants?
"The age range for patients that this clinical trial is willing to accept begins at 18 years old and ends at 65 years old."
Are there different sites where this trial is taking place?
"Picking from 31 available locations, patients can choose the site nearest them to help reduce travel demands."
Are there any more patients needed to participate in this clinical trial?
"Yes, this trial is currently open for recruitment and has been since August 18th, 2022 according to the listing on clinicaltrials.gov."
Could I be a candidate for this clinical research?
"470 individuals aged 18-65 who have had covid19 in the past 3 months and are experiencing new or worsening pain that began around the time of their initial infection are eligible for this study."
How many individuals are currently signed up for this clinical trial?
"That is correct. The study, which was first announced on August 18th, 2020 is still recruiting the 470 patients it needs from 31 different locations."
Has the FDA sanctioned TNX-102 SL for therapeutic use?
"There is some data supporting the safety of TNX-102 SL, but none indicating that it is an effective treatment. It received a score of 2."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger